Skip to main content
Log in

Causes of death of mutation carriers in Finnish Lynch syndrome families

  • Original Article
  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

Lynch syndrome (LS) is an autosomal dominant cancer syndrome including increased life-long risk for colorectal (CRC) and endometrial (EC) cancer, but also for cancers of other types. The risk for CRC is up to 70–80 % and for EC up to 50–60 %. Due to screening and early diagnosing the mortality related to CRC and EC seems to be low. In spite of many studies on surveillance of mutation carriers, there is no comprehensive evaluation on causes of death in LS families. The disease history and cause of death of all the deceased, tested mutation carriers and their mutation negative relatives in the Finnish LS families (N = 179) was examined utilizing hospital records and relevant national registries. Out of 1069 mutation carriers 151 had succumbed; 97 (64 %) from cancer. Out of 1146 mutation-negative family 44 members had died; 11 (25 %) of them from cancer. In 12 (7.7 %) of the deceased mutation carriers no cancer had been diagnosed. The mean age of death from cancer was 63.2 years vs. 68.8 years from non-cancer causes. Only 7.9 % of the patients with CRC had died from CRC and 5 % of those with EC, respectively. 61 % of the cancer deaths were related to extra-colonic, extra-endometrial cancers. The cumulative overall and cancer specific death rates were significantly increased in Mut+ compared to Mut− family members. Even surveillance yields decrease in the life-long risk and mortality of the most common cancers CRC and EC in LS, almost all mutation carriers will contract with cancer, and two thirds of the deceased have died from cancer. This should be taken in account in genetic counseling. Mutation carriers should be encouraged to seek help for abnormal symptoms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

HNPCC:

Hereditary non-polyposis colorectal cancer

LS:

Lynch syndrome

MMR:

Mismatch repair

CRC:

Colorectal cancer

EC:

Endometrial cancer

Mut+:

Tested mutation carriers

Mut−:

Tested mutation-negative family member

References

  1. Aaltonen L, Johns L, Järvinen H et al (2007) Explaining the familial colorectal cancer risk associating with mismatch repair (MMR) deficient and MMR-stable tumors. Clin Cancer Res 13:356–361

    Article  PubMed  CAS  Google Scholar 

  2. Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international group on HNPCC. Gastroenterology 116:1453–1456

    Article  PubMed  CAS  Google Scholar 

  3. Hampel H, Stephens JA, Pukkala E et al (2005) Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. Gastroenterology 129:415–421

    PubMed  Google Scholar 

  4. Mecklin J-P, Aarnio M, Läärä E et al (2007) Development of colorectal tumors in colonoscopic surveillance in Lynch Syndrome. Gastroenterology 133:1093–1098

    Article  PubMed  Google Scholar 

  5. Järvinen HJ, Mecklin JP, Sistonen P (1995) Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 108:1405–1411

    Article  PubMed  Google Scholar 

  6. Vasen HFA, Abrdirahman M, Brohet R et al (2010) One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. Gastroenterology 138:2300–2306

    Article  PubMed  Google Scholar 

  7. Watson P, Vasen HFH, Mecklin J-P et al (2008) The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer 123:444–449

    Article  PubMed  CAS  Google Scholar 

  8. Vasen HF, Wignen JT, Menko FH et al (1996) Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 110:1020–1027

    Article  PubMed  CAS  Google Scholar 

  9. Järvinen HJ, Renkonen-Sinisalo L, Aktan-Collan K et al (2009) Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol 27:4793–4797

    Article  PubMed  Google Scholar 

  10. Järvinen HJ et al (2000) Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 118:829–834

    Article  PubMed  Google Scholar 

  11. Mecklin JP, Järvinen HJ, Peltokallio P (1986) Identification of cancer family syndrome. Gastroenterology 90:1099

    PubMed  CAS  Google Scholar 

  12. Pylvänäinen K, Kairaluoma M, Mecklin J-P (2006) Compliance and satisfaction with long-term surveillance in Finnish HNPCC families. Fam Cancer 5:173–178

    Article  Google Scholar 

  13. Parry S, Aung KW, Parry B et al (2011) Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 60:950–957

    Article  PubMed  Google Scholar 

  14. Nieminen T, Gylling A, Abdel-Rahman WM et al (2009) Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. Clin Cancer Res 15:5722–5783

    Article  Google Scholar 

  15. Burn J, Gerdes A-M, Macrae F et al (2011) Long-term effect of aspiring on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 378:2081–2087

    Article  PubMed  Google Scholar 

  16. Aktan-Collan K, Haukkala A, Mecklin JP, Uutela A, Kääriäinen H (2001) Psychological consequences of predictive genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a prospective follow-up study. Int J Cancer 93:608–611

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

The study was supported by the Finnish Cancer Foundation and Central Finland Health Care District (TEVO).

Ethical standards

This study has been proved by Ministry of Social Affairs and Health Dnro 56/08/80.

Conflict of interest

None declared.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kirsi Pylvänäinen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pylvänäinen, K., Lehtinen, T., Kellokumpu, I. et al. Causes of death of mutation carriers in Finnish Lynch syndrome families. Familial Cancer 11, 467–471 (2012). https://doi.org/10.1007/s10689-012-9537-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-012-9537-3

Keywords

Navigation